Alnylam Pharmaceuticals (ALNY) Long-Term Debt Repayments (2025)
Alnylam Pharmaceuticals (ALNY) posted Long-Term Debt Repayments of $52.3 million for Q4 2025, down 95.29% on a QoQ basis from $1.1 billion in Q3 2025.
Alnylam Pharmaceuticals (ALNY) Long-Term Debt Repayments (2025) Analysis & Trends
Alnylam Pharmaceuticals' Long-Term Debt Repayments history runs 1 years deep, the most recent figure standing at $52.3 million for Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.64 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 52.30 Mn |
| Dec 31, 2025 | 52.30 Mn |
| Sep 30, 2025 | 1.11 Bn |
| Sep 30, 2025 | 1.11 Bn |